X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES GSK PHARMA JUBILANT LIFE SCIENCES/
GSK PHARMA
 
P/E (TTM) x 16.5 67.4 24.5% View Chart
P/BV x 4.3 13.6 32.0% View Chart
Dividend Yield % 0.4 1.1 39.5%  

Financials

 JUBILANT LIFE SCIENCES   GSK PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
GSK PHARMA
Mar-18
JUBILANT LIFE SCIENCES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1872,760 6.8%   
Low Rs652,040 3.2%   
Sales per share (Unadj.) Rs364.3339.0 107.5%  
Earnings per share (Unadj.) Rs6.841.4 16.5%  
Cash flow per share (Unadj.) Rs24.545.9 53.4%  
Dividends per share (Unadj.) Rs3.0035.00 8.6%  
Dividend yield (eoy) %2.41.5 163.3%  
Book value per share (Unadj.) Rs164.9242.9 67.9%  
Shares outstanding (eoy) m159.2884.70 188.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.37.1 4.9%   
Avg P/E ratio x18.457.9 31.7%  
P/CF ratio (eoy) x5.152.3 9.8%  
Price / Book Value ratio x0.89.9 7.7%  
Dividend payout %43.884.5 51.9%   
Avg Mkt Cap Rs m20,061203,280 9.9%   
No. of employees `0006.2NA-   
Total wages/salary Rs m11,0525,234 211.2%   
Avg. sales/employee Rs Th9,383.0NM-  
Avg. wages/employee Rs Th1,786.9NM-  
Avg. net profit/employee Rs Th176.3NM-  
INCOME DATA
Net Sales Rs m58,03428,715 202.1%  
Other income Rs m191545 34.9%   
Total revenues Rs m58,22429,260 199.0%   
Gross profit Rs m5,7865,059 114.4%  
Depreciation Rs m2,812380 739.9%   
Interest Rs m3,2372 161,860.0%   
Profit before tax Rs m-725,222 -1.4%   
Minority Interest Rs m-2860-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m2,145178 1,205.0%   
Tax Rs m6961,892 36.8%   
Profit after tax Rs m1,0903,508 31.1%  
Gross profit margin %10.017.6 56.6%  
Effective tax rate %-965.936.2 -2,665.9%   
Net profit margin %1.912.2 15.4%  
BALANCE SHEET DATA
Current assets Rs m29,28021,815 134.2%   
Current liabilities Rs m38,91215,999 243.2%   
Net working cap to sales %-16.620.3 -81.9%  
Current ratio x0.81.4 55.2%  
Inventory Days Days8464 132.7%  
Debtors Days Days5119 271.2%  
Net fixed assets Rs m55,71212,475 446.6%   
Share capital Rs m155847 18.2%   
"Free" reserves Rs m20,96819,726 106.3%   
Net worth Rs m26,26520,573 127.7%   
Long term debt Rs m17,1696 286,146.7%   
Total assets Rs m88,60639,475 224.5%  
Interest coverage x1.02,612.0 0.0%   
Debt to equity ratio x0.70 224,136.9%  
Sales to assets ratio x0.70.7 90.0%   
Return on assets %4.98.9 54.9%  
Return on equity %4.217.1 24.3%  
Return on capital %11.626.2 44.1%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,004564 3,901.4%   
Fx outflow Rs m11,7497,429 158.1%   
Net fx Rs m10,255-6,865 -149.4%   
CASH FLOW
From Operations Rs m8,0264,728 169.8%  
From Investments Rs m-1,744-1,042 167.4%  
From Financial Activity Rs m-4,447-3,066 145.0%  
Net Cashflow Rs m1,834620 296.0%  

Share Holding

Indian Promoters % 45.6 0.0 -  
Foreign collaborators % 3.5 50.7 6.9%  
Indian inst/Mut Fund % 8.7 10.2 85.3%  
FIIs % 21.2 23.8 89.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 15.4 137.0%  
Shareholders   23,815 102,036 23.3%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  SUVEN LIFE  

Compare JUBILANT LIFE SCIENCES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY18); Net Profit Up 1.4% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 1.4% YoY). Sales on the other hand came in at Rs 23 bn (up 37.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Aug 14, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - ALKEM LABORATORIES COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS